Epitranscriptomic Switch in Renal Fibrosis: Pathogenic Mechanisms of m⁶A Methylation Machinery and the Advent of CRISPR-Based RNA Editing
##1. A New Layer of Gene Regulation: m⁶A Epitranscriptomic Control Traditional kidney disease research has focused primarily on DNA sequence variants and transcription-level epigenetics, but recent studies have highlighted N6‑methyladenosine (m⁶A)—the most prevalent internal modification of mRNA and non‑coding RNA (ncRNA)—as a central axis of gene regulation. m⁶A dynamically governs RNA splicing, stability, and translational efficiency through the coordinated action of writer, eraser, and reader protein complexes. Disruption of this epitranscriptomic system can directly precipitate kidney disease by excessively amplifying or suppressing the expression of specific genes.
##2. Aberrant m⁶A Regulation and the Formation of Renal Fibrosis Networks The investigators demonstrated causal links between dysregulated m⁶A machinery and pathological pathways in both acute and chronic kidney disease models. Notably, abnormal m⁶A methylation increased the stability of pro‑fibrotic factor mRNAs while promoting the degradation of protective transcripts, thereby directly aggravating renal fibrosis. Moreover, m⁶A‑modified ncRNAs were shown to integrate into pro‑fibrotic and immune‑inflammatory networks as regulatory nodes, establishing complex feedback loops that accelerate disease progression.
##3. Next‑Generation Therapeutic Strategies: From Small‑Molecule Inhibitors to CRISPR‑Cas13 Editing These findings have opened avenues for precision targeting of the m⁶A machinery. Small‑molecule inhibitors that block the activity of specific writers or readers are under development, but off‑target toxicity upon systemic administration remains a major obstacle. As a breakthrough, CRISPR‑Cas13‑based epitranscriptome editing technologies capable of selectively removing or adding m⁶A at defined RNA sequences are gaining attention. This approach targets pathogenic transcripts rather than the enzymes themselves, thereby maximizing tissue specificity.
##4. From Irreversible Renal Fibrosis to Reversible Recovery via Transcriptomic Programming The significance of this review and the latest insights lies in the demonstration that renal fibrosis—long considered irreversible—can be subjected to reversible, transcript‑level control. By toggling the m⁶A switch of specific fibrotic genes on or off, upstream protein targets that are inaccessible to conventional drugs can be preemptively suppressed. This paradigm not only facilitates the discovery of diagnostic biomarkers for refractory kidney diseases but also underpins the development of RNA‑based precision therapeutics.
Source: Epitranscriptomic Regulation in Kidney Disease, 2026.
Summary: Epitranscriptomic regulation, particularly m⁶A RNA methylation, has emerged as a crucial driver of renal pathophysiology. Dysregulation of m⁶A writers, erasers, and readers dynamically alters RNA stability and splicing, exacerbating renal fibrosis and immune responses, partly through m⁶A-modified non-coding RNAs. Emerging therapeutic strategies, notably targeted CRISPR-Cas13-based epitranscriptome editing and small-molecule inhibitors, offer a paradigm shift toward precision medicine, although optimizing tissue-specific delivery and minimizing systemic toxicity remain key challenges.
This dataset comprehensively illustrates how epitranscriptomic regulation serves as a fundamental pathogenic mechanism in renal fibrosis. By highlighting m⁶A as the pivotal link between protein‑coding genes and non‑coding RNAs, it provides unique scholarly evidence that CRISPR‑based RNA editing can become a next‑generation weapon for kidney‑targeted gene therapies.